Mesoporous organosilica nanoparticles (PHT-PMO) have been prepared from an octa-triethoxysilylated Zn phthalocyanine precursor. These PHT-PMO nanoparticles had no dark toxicity but high phototoxicity when irradiated at 650 nm, and remarkable near-infrared phototoxicity when excited at 760 and 810 nm. The PHT-PMO were then aminated to promote electrostatic complexation with siRNA. Transfection experiments were performed upon NIR irradiation and photochemical internalization was very efficient, leading to 65% luciferase extinction in MCF-7 cancer cells expressing stable luciferase.
30 December 2020 in Celal Bayar Üniversitesi Fen Bilimleri Dergisi
Used as photosensitizer in photodynamic therapy, phthalocyanines exhibit their long wavelength absorption and the ability to produce high singlet oxygen for tumor destruction with 650 to 800 nm fluorescence.Phthalocyanines with their long wavelength absorption and fluorescence from 650 to 800 nm exhibit their ability to produce high singlet oxygen for the destruction of tumors. In this study, new axial substituted silicon(IV) phthalocyanine (4) was synthesized. Unsubstituted dichlorosilicon phthalocyanine was synthesized from 1,3-diiminoisoindoline via cyclotetramerization. The axial substitution reaction was carried out using dichlorosilicon(IV) phthalocyanine and excess of 2-methoxyethanol. Structural characterization of this new axial-substituted silicon(IV) phthalocyanine by IR, mass, and UV-Vis spectroscopy were performed. Photochemical properties were investigated for cancer therapy. In this study, we found that axial substituted silicon(IV) phthalocyanine (4) may be promising PDT agent.
31 May 2022 in Journal of the Turkish Chemical Society Section A: Chemistry
Photodynamic therapy is a highly specific and clinically approved method in which a non-toxic photosensitizer drug is administered to the patient for cancer treatment. Phthalocyanines with their long wavelength absorption and fluorescence from 650 to 800 nm can be used as photosensitizers for photodynamic therapy and are used in clinical trials. In this study, functional novel axially substituted silicon (IV) phthalocyanine (PS-2) was synthesized. Unsubstituted dichlorosilicon (IV) phthalocyanine was synthesized from 1,3-diiminoisoindoline via cyclotetramerization. The axial substitution reaction was carried out using dichlorosilicon (IV) phthalocyanine and excess of N-Boc-ethanolamine. Structural characterization of this novel PS-2 by FT-IR, mass, 1H NMR and UV-Vis spectroscopy were performed. Photochemical properties (photo degradation quantum yields (d) and singlet oxygen quantum yield () of PS-2, which are the first steps for cancer treatment, were investigated.